Clinical Trial Update: Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial of sorafenib for hormone-naïve biochemical recurrence of prostate cancer was withdrawn, with no results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN